What kind of drug is Rubicatin? Is it available in the country?

Lurbinectedin (Lurbinectedin), also known as Zepzelca, is an innovative anti-cancer drug. Its core role is as an alkylating agent and a selective inhibitor of oncogenic transcription. It can preferentially bind to guanine residues in the minor groove of DNA to form specific adducts and cause changes in the DNA helical structure. This change affects the activity of DNA-binding proteins, especially certain transcription factors and DNA repair pathways, thereby inhibiting oncogenic transcription and leading to tumor cell apoptosis.

In terms of indications, rubicatin is specifically targeted at adult patients with metastatic small cell lung cancer (SCLC) whose disease has progressed after platinum-based chemotherapy. Its efficacy has been verified in clinical trials, providing new treatment options for these patients.

However, in the domestic market, the launch situation of Rubicatin is slightly different. Although the drug has been approved in many countries and regions around the world, including the U.S. Food and Drug Administration (FDA) which officially approved it in June 2020, it has not yet been officially launched in mainland China. However, it is worth mentioning that rubicatin received emergency clinical use approval from the Hainan Medical Products Administration in July 2022 and received marketing approval in Macau, China in February 2024 for the treatment of patients with metastatic small cell lung cancer who have progressed after receiving platinum-based chemotherapy.

The introduction of rubicatin is of great significance for the treatment of lung cancer. It not only provides new treatment strategies, but its unique mechanism of action also provides new directions for future drug development. Although it has not yet been officially launched in mainland China, with the deepening of clinical research and the advancement of regulatory approval, we have reason to believe that Rubicatin will soon bring good news to domestic patients.